Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive Crisis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorImam Abdulrahman Bin Faisal University

About this trial

Sickle cell disease (SCD) is a prevalent inherited blood disorder characterized by vaso-occlusive crises (VOCs), which lead to severe pain and complications. Despite hydration being a cornerstone of VOC management, the optimal fluid strategy remains uncertain. This study evaluates restrictive versus liberal fluid management strategies in patients with acute VOC.

This multi-center, open-label, non-inferiority RCT will enroll patients with SCD presenting with acute VOC. Participants will be randomized to either a restrictive or liberal intravenous fluid management protocol. Primary outcome is pain score reduction. Secondary outcomes include time to pain resolution, ED length of stay, hospital admission rate, cumulative opioid dose, adverse events (incidence of fluid overload, pulmonary congestion), acute chest syndrome, incidence of acute kidney injury, revisit rates within 72 hours of ED discharge, need for intensive care or high-dependency unit admission, need for additional interventions, and 28 days overall mortality. Data will be analyzed using intention-to-treat principles.

We hypothesize that a restrictive fluid strategy will achieve non-inferior pain control compared to a liberal strategy, while minimizing fluid-related complications. This study will provide evidence to inform clinical guidelines for fluid management in SCD patients experiencing VOCs.

Eligibility criteria

Qualifiers

Patients >18 years old with a confirmed diagnosis of SCD.

Presenting with a VOC.

NPRS >5

Willingness to participate and provide informed consent.

Disqualifiers

Patient requiring specialized IVF management as per the treating physician discretion.

Patients with congestive heart failure, and /or acute or chronic symptomatic systolic heart failure

Patients with ESRD on chronic dialysis

Patients with signs of shock (low SBP <100 or MAP < 65) and signs of hypo perfusion

Trial design

Treatments tested in this trial

  • Sodium Chloride (NaCl) 0.9 %
  • Sodium Chloride (NaCl) 0.9 %

Treatment groups

394 Participants
are divided into 2 treatment groups